Personalized medicine in nonalcoholic fatty liver disease
Carlos J. Pirola, Silvia Sookoian
Clin Mol Hepatol. 2022;28(4):935-938.   Published online 2022 Jun 24     DOI: https://doi.org/10.3350/cmh.2022.0175
Citations to this article as recorded by Crossref logo
Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making
Carlos J Pirola, Silvia Sookoian
Expert Review of Gastroenterology & Hepatology.2023; 17(4): 317.     CrossRef
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184.     CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261.     CrossRef